News|Articles|July 1, 2026

9 Endocrinology Headlines You Missed in June 2026

Catch up on major trial results, groundbreaking FDA decisions, and key clinician insights from major endocrinology conferences.

June was a very active month for endocrinology, with major US Food and Drug Administration (FDA) approvals and a pair of major conferences. The FDA granted clearance to new devices for type 1 diabetes (T1D) while the Endocrine Society (ENDO) Annual Meeting 2026 and the American Diabetes Association (ADA) Scientific Sessions 2026 brought with them a substantial number of major trials in obesity and type 2 diabetes (T2D).

Related to this article

Ania Jastreboff, MD, PhD | Image Credit: Yale School of Medicine

September 29th, 2026

Retatrutide Improves Weight Loss, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo

Newly published results from the TRIUMPH-1 study have indicated the direct correlation between the triple agonist and several improvements to weight.

September 29th, 2026

Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D

Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.

September 24th, 2026

Diabetes Dialogue: Weekly Insulin Efsitora Alfa Gets FDA Approval for Type 2 Diabetes

Discover how newly cleared weekly basal insulin efsitora reshapes type 2 diabetes care—QWINT results, hypoglycemia edge, and dosing tips.

September 24th, 2026

Weekly Insulin Efsitora Alfa (Onswik) Gains FDA approval for Type 2 Diabetes

FDA clears Eli Lilly’s Onswik weekly insulin from QWINT trials, cutting injections for type 2 diabetes while matching daily basal control.

September 28th, 2026

Skin of Color Savvy: Reimbursement, Coverage, and Care Gaps for Patients With Skin of Color

Murad Alam, MD, and Elizabeth Kiracofe, MD, discuss how reimbursement, coverage, and advocacy shape dermatology access for patients with skin of color.

September 26th, 2026

The HCPFive: Top News for Healthcare Providers from the Week of 09/20

Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).

Image Credit: US Food and Drug Administration

September 25th, 2026

Zilurgisertib Receives FDA Approval for FOP in Patients 12 and Older

The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.

September 24th, 2026

The Medical Sisterhood: Is Becoming a Doctor Still Worth It?

Andrea Murina, MD, weighs whether she would recommend medicine to her own children amid AI, physician burnout, and evolving residency training standards.